Kenta Biotech kentabiotech.com


Kenta Biotech is focusing on the discovery and development of fully human monoclonal antibodies for the life-saving treatment of patients with serious infectious diseases.

Kenta Biotech is focusing on the discovery and development of fully human monoclonal antibodies for the life-saving treatment of patients with serious infectious diseases.

Company (Alive / Active)

Phone:

Fax:

Rehhagstrasse 79
CH - 3018
Switzerland

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Kenta Biotech $0M Nov 30, 2018
See all 17 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Kenta Biotech Jobs

jobs by Indeed job
						search
There is no Investors data available for this company. Please select another tab.
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Idenix Pharmaceuticals

Cambridge, Massachusetts, United States
AcquiredIdenix Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix is headquartered in Cambridge, Massachusetts (USA). The Company's clinical development operations and drug discovery operations are conducted in Cambridge and in the Company's European laboratories in Montpellier, France. Idenix's current focus is on the treatment of patients with hepatitis C infection.Login to see details

Viventia

Winnipeg, Manitoba, Canada
AcquiredViventia, fka Novopharm Biotech, is a biopharmaceutical company that designs, develops, engineers, and commercializes protein therapeutic technology and advanced monoclonal antibody products designed to offer safer, more beneficial therapies for those who suffer from cancer. Viventia is employing its monoclonal antibody discovery and development platforms to discover, validate, and advance a portfolio of new antibody products based on oncology drug targets.Login to see details
See all 17 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Human monoclonal antibody specific for lipopolysaccharides (lps) of the Feb 13, 2006 Jun 12, 2012 Patent
Human monoclonal antibody specific lipopolysaccharides (lps) of serotype iats 06 of Nov 10, 2005 Oct 06, 2009 Patent